Paper Details

  1. Home
  2. Paper Details

[Unusual association of BRAF and MEK inhibitors: Clinical response of metastatic melanoma treated with dabrafenib-cobimetinib].

Author: CupissolDidier, EvrardAlexandre, LeenhardtFanny, LesageCandice, MbatchiLitaty

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
English AbstractA summary of a research paper/publication written in English for a wider audience.
LetterA written message for communication and exchange of information between individuals.

Overview

A patient with metastatic melanoma achieved complete remission for 19 months using an off-label combination of dabrafenib (BRAFi) and cobimetinib (MEKi). This unusual combination was used to manage pyrexia and was closely monitored using therapeutic drug monitoring. This case report highlights the potential benefit of personalized treatment strategies in melanoma management.
Paper Details　
Original Abstract of the Article :
Despite the efficacy of targeted therapies in melanoma, the management of adverse events with BRAFi and MEKi (inhibitors) is one of the limits of these treatments. Close monitoring is required to ensure efficacy and patient safety. In this case study, we report a patient treated for metastatic melan...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.bulcan.2023.02.019

データ提供：米国国立医学図書館（NLM）

An Unexpected Oasis: Dabrafenib-Cobimetinib for Metastatic Melanoma

The treatment of metastatic melanoma, like navigating a treacherous desert, often involves complex and challenging therapies. This study, like a serendipitous discovery of a hidden oasis, reports a unique case of a patient with metastatic melanoma who experienced complete remission after being treated with an unusual combination of dabrafenib and cobimetinib. The researchers, like skilled desert explorers, meticulously documented the patient's response to this innovative treatment approach.

Dabrafenib-Cobimetinib: A New Path to Remission

This study, like a beacon of hope in the vast desert of melanoma treatment, highlights the potential of this unconventional combination therapy. The researchers, like skilled desert navigators, used therapeutic drug monitoring to carefully manage the patient's treatment, ensuring both efficacy and safety. This study, like a testament to the power of clinical ingenuity, demonstrates the potential of this off-label combination for achieving complete remission in metastatic melanoma, offering a new path to hope for patients with this challenging disease.

Navigating the Desert of Cancer Treatment: Embracing Innovation

This research, like a well-worn path in the desert, serves as a reminder that the search for effective cancer therapies is an ongoing journey. The study emphasizes the importance of embracing innovative approaches and exploring new combinations of drugs to personalize treatment and optimize outcomes. This study, like a testament to the resilience of the human spirit, encourages continued research to explore the potential of unconventional therapies and advance the fight against cancer.

Dr.Camel's Conclusion

This case study offers a compelling example of the potential of dabrafenib-cobimetinib combination therapy for achieving complete remission in metastatic melanoma. The findings highlight the importance of embracing innovative approaches and exploring new treatment strategies to personalize care and improve outcomes for patients with cancer.

Date :
  1. Date Completed 2023-06-23
  2. Date Revised 2023-06-23
Further Info :

Pubmed ID

36966054

DOI: Digital Object Identifier

10.1016/j.bulcan.2023.02.019

Related Literature

Article Analysis
・Effects of dabrafenib・Effects of cobimetinib
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.